Clinical Trial Update: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. [Phase 3]

View source ↗

Summary

This clinical-trial update announces a Phase 3 study evaluating QL1706, a PD-1/CTLA-4 bispecific antibody, in combination with chemoradiotherapy for locoregiona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• QL1706 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Sun Yat-Sen University Cancer Center | Conditions: Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Status: RECRUITING